Although anti-MSLN CAR-like NK cells have demonstrated potent antitumor activity in vivo, the dense extracellular matrix and high interstitial pressure of solid tumor tissue often limit the infiltration capacity of immune cells, thereby compromising therapeutic efficacy.9 To enhance the penetration of anti-MSLN CAR-like NK cells into the tumor stroma and further improve antitumor efficacy, we conjugated the tumor-penetrating peptide uCendR (RPARSGR↓SAGGSVA)17 to the MSLN end. Here, MSLN is linked to neoplasm.